Key Speakers
Dr Sven Stegemann, Director Global
Pharmaceutical Business Development, Capsugel
Dr Richard White, Manager Toxicology and Pharmacology, OphthalmoPharma
Dr Cornelus van Nostrum, Associate Professor, Department of Pharmaceutics,
Utrecht Institute of Pharmaceutical Sciences
Professor Andreas Bernkop-Schnuerch, Chief Scientific Officer, University
of Innsbruck
Dr Peter Scholes, Vice President Pharmaceutical Sciences, Pharmaceutical
Profiles
Dr Woei Ping Cheng, Lecturer in Pharmaceutics, School of Pharmacy and
Life Sciences, The Robert Gordon University
Professor Amnon Hoffman, Chairman, Dept. of Pharmaceutics, School of
Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem
Professor Alfred Fahr, Chair of Pharmaceutics, Fredrich Schiller
University of Jena
Randy Mellaerts, Centre for Surface Science Catalysis, University of
Leuven
Professor Howard Stevens, Assistant Head of Institute and Professor of Drug
Delivery, University of Strathclyde
Conference Introduction
Drug Formulation Technologies 4th
5th November 2008 , London, UK
Dear Colleague,
A great deal of publicity has emerged with
respect to drug-delivery systems in relation to innovation in the fi eld of
formulation. These technologies have ultimately
been designed to improve the effi cacy of chemical entities and deliver the
desired therapeutic effect of drugs, both novel and established, which are
available in
todays healthcare and affi liated markets.
The need to address formulation issues occurs in
a number of industries from: agriculture - with respect to fertilisers and
pesticides; to the development of pharmaceuticals as found in biology and
medicine; as well as in the chemicals industry for the manufacture of high
performance paints and pigments. With advancements in technology, formulations
being developed through nanoscience (for example) are enabling technology
transfer to work across these industrial
sectors, which is creating a stimulating environment for innovation.
Visiongains Drug Formulation Technologies 2008
conference, will ultimately create the appropriate environment for an exchange
of key concepts and ideas with respect to developments in formulation
technologies all occuring across drug-delivery platforms in the healthcare
industry.
The predominant focus of this conference will be
in advancements being made in the field of formulation in terms of drug
development research in areas including
dissolution, solubilisation, and optimised stability, as well as fi nal dosage
forms ready to be used in combination with novel or improved drug-delivery
systems.
Reasons to register today
To gain a current and focused overview of formulation technologies in the drug
industry
To assess and forecast the future of innovation in the drug formulations
affiliated industries
To understand the issues faced in aligning drug formulation with drug-delivery
To develop an up-to-date understanding of the product management framework
created by Speciality Pharma business-models
To explore integrated business-network solutions in order to troubleshoot
Pharma pipeline projects associated with formulation
To determine the viability of current research into new and emerging areas of
formulation technology in relation to nanoscience
To create a suitable networking environment for the appropriate senior
business developers and scientific leaders in the industry
I look forward to meeting you at this conference,
Best regards,
Toby Roy
Conference Producer
Who will attend?
CEOs, Directors, Senior Business
Developers, Senior and Chief Scientific Officers, Formulation and
Pre-formulation Experts and
Specialists, Drug-delivery teams,
and Consultants from:
Pharmaceutical and Biotechnology
companies
The Speciality Pharma industry
Drug-delivery technology companies
The Generic-based Pharma & Biotech industries
Contract Research Organisations
Regulatory Bodies
Outsourcing-based organisations: Manufacturing and Equipment based
Investment and Finance-based companies
Marketing-based organisations
Day 1 (Drug Formulation
Technologies Tuesday 4th November 2008)
Drug Formulation Technologies
Tuesday 4th November 2008
09:30 Registration and refreshments
10:00 Opening address from the chair
Dr Sven Stegemann
Director Global Pharmaceutical Business
Development
Capsugel
10:10 A novel delivery system aimed
to enhanced the oral bioavailability of lipophilic P-gp substrate drugs
10:50 In vitro In vivo Correlation (IVIVC): Application to formulation design,
bioequivalence, & dissolution specifications
Fiona McInnes
Lecturer
University of Strathclyde*
11:30 Morning refreshments
11:50 Ordered mesoporous silica as a carrier for poorly
water soluble drugs
Dissolution enhancement of poorly
water soluble drugs
Tailor made design of silica based carrier materials
Supersaturation of itraconazole in biorelevant media
Biopharmaceutical evaluation of ordered mesoporous silica
Randy Mellaerts
Centre for Surface Science Catalysis
University of Leuven
12:30 Liposomal formulations for
poorly soluble drugs
Which pre-requisites has a drug to have to be successfully formulated in
liposomes?
Biophysics as essential methodology for identifying compatibility problems
Successful formulations on the market - case study: photosensitiser
formulation in liposomes unexpected advantages.
Professor Alfred Fahr
Chair of Pharmaceutics
Fredrich Schiller University of Jena
13:10 Networking lunch
14:30 Design of transdermal gels for
systemic drug delivery
Advantages of transdermal gels
compared to patches
Drug selection criteria for suitability to transdermal drug delivery
General formulation composition and attributes
In vitro testing of formulation prototypes
Prediction of in vivo performance based on in vitro testing
Formulation stability issues
Dr Ingo ALBERTI
Head of Preclinical Development
Antares Pharma
15:10 The use of amphiphilic
polymers as emerging delivery systems for small drug molecules and
macromolecules
Overview of amphiphilic polymers
vs. conventional surfactants
The use of these systems in addressing the challenges in hydrophobic drug
solubilisation and protein delivery
Evaluate the advantages and limitations of the delivery systems
Future direction of the delivery systems, looking at preclinical and clinical
studies
Dr Woei Ping Cheng
Lecturer in Pharmaceutics, School of
Pharmacy and Life Sciences
The Robert Gordon University
15:50 Afternoon refreshments
16:10 Application of solid
dispersion and nanoparticulate formulation technologies for poorly soluble drug
candidates
Identification of solid
dispersions and nanoparticulate formulations as technologies to overcome poor
solubility and bioavailability issues
The importance of elucidating the background to these approaches with respect
to the increasing numbers of products appearing in the market
Discussion of former hurdles and current improvements of understanding,
selecting, and applying technologies successfully to new molecules
Case study discussion illustrating a solvent based process for making solid
dispersions, illustrating current achievements in this field
16:30 Drug Delivery and
individualised therapy: Towards flexibility in development and manufacturing
Overview of multiparticulate drug
delivery systems for immediate and modified release
Introduction into lipid drug delivery systems to enhance bioavailability
Understand the improved PK profile of multiparticulate and liquid drug
delivery systems
Select the most flexible dosage form to cope with the increasing dose ranges
Dr Sven Stegemann
Director Global Pharmaceutical Business
Development
Capsugel
17:10 Closing remarks from the chair
17:15 Networking drinks reception
Take your discussions further and build new relationships in a relaxed and
informal setting.
Day 2 (Drug Formulation
Technologies Tuesday 4th November 2008)
09:30 Registration and refreshments
10:00 Opening address from the chair
Dr. Cornelus van Nostrum
Associate Professor, Department of Pharmaceutics
Utrecht Institute of Pharmaceutical Sciences
10:10 Understanding the performance
of drug delivery
systems in man
Use of old excipients to develop novel drug formulation strategies
Case studies in oral and nasal drug delivery
Using gamma scintigraphy to visualise in-vivo performance of formulations
Quantification of in-vivo behaviour of pharmaceutical formulations
Professor Howard Stevens
Assistant Head of Institute and Professor of Drug Delivery
University of Strathclyde
10:50 Multifunctional polymeric
excipients: teaching
(old) drugs new tricks
Types of polymeric excipients
Mucoadhesive, in-situ gelling, release controlling, permeation
enhancing and efflux pump inhibiting properties
Proof of principle studies
Safety aspects
Prof. Dr. Andreas Bernkop-Schnuerch
Chief Scientific Officer
University of Innsbruck
11:30 Morning refreshments
11:50 Formulation strategies for use
in injectable or
inhalation sevices
Analysis of attempts at delivery via the oral route the prospects for
biopharmaceuticals in upcoming years
The surge in formulations for antibodies:promising routes of delivery
Fresh approaches to protein formulation and delivery
12:30 Modified Release oral
formulations: Using human
regional bioavailability data to ensure success and
maximise value
Identifying the critical drivers
for MR formulation technology selection
Confirming the potential oral developability of the candidate molecule
versus the proposed target product profile
Selecting the most appropriate drug delivery and/or solubilisation
technologies to achieve the desired pharmacokinetic (PK) delivery profile
Using regional bioavailability data to generating a proactive MR
formulation road-map to expedite initiation of PoX studies
Opportunities for enhanced formulation IP protection by strengthening
the inventive step
Dr Peter Scholes
VP Pharmaceutical Sciences
Pharmaceutical Profiles Ltd
13:10 Networking lunch
14:30 Challenges and solutions at
the manufacturing stage of the drug delivery process
James Drinkwater
Process Director Bioquell UK, Vice
Chairman
Pharmaceutical and Healthcare Sciences Society*
15:10 Systems for regio-selective
drug delivery in the gastrointestinal tract
Absorption windows along the GI
tract
Controlled Release - Gastroretentive Dosage Forms (CR-GRDF)
Drugs that would benefit from CR-GRDF
Lipid vehicles for lipophilic drugs - Intelligent selection
Lymphatic transport
Prof. Amnon Hoffman
Chairman, Dept. of Pharmaceutics,
School of Pharmacy, Faculty of Medicine
The Hebrew University of Jerusalem
15:50 Afternoon refreshments
16:10 Mono-substituted cyclodextrins
in ocular reformulation
Beta Monosubstituted Cyclodextrins
are complex, water-soluble glucose oligomers with a hydrophobic core.
The core hydrophobicity makes them drug delivery vehicles for insoluble or
poorly water-soluble compounds.
Capture candidates include steroids, peptides, natural compounds and a host of
small to large molecular weight drug candidates.
Once diluted in a complex fluid like tears, the on-off equilibrium favours
slow release increasing the half-life and favouring better ocular penetration
Dr Richard White
Manager Toxicology and Pharmacology
OphthalmoPharma
16:50 Design of polymeric micelles
as true carriers for the controlled delivery of hydrophobic drugs
Use of thermosensitive polymers
enables convenient and continuous formulation process
Transient stability of micelles provides delayed drug release
Systemic drug circulation time and biodistribution can be improved by
crosslinking of the micelles
Aiming for chemotherapy and photodynamic therapy of cancer
Prospects for oral delivery will be discussed
Dr. Cornelus van Nostrum, Ph.D.
Associate professor, Department of
Pharmaceutics
Utrecht Institute of Pharmaceutical
Sciences
17:30 Chairs closing remarks and
end of conference
.
